Evolving Paradigms in Transplant-Related CMV Prevention and Management: Setting Foundations for Improved Patient Outcomes

Cytomegalovirus (CMV) infection is an important complication and risk factor for nonrelapse mortality in patients who undergo hematopoietic stem cell transplantation (HSCT). Historically, therapies for the prevention of infections in patients who are CMV-seropositive have been associated with significant adverse events. There is also an urgent need in patients with treatment-resistant CMV infections for novel therapies that have fewer toxicities, greater potency, and lack of cross-resistance with current antiviral therapies.

 

This activity is supported by educational grants from Takeda Pharmaceuticals USA, Inc.; and Merck & Co., Inc.

 

Target Audience

This educational program is directed toward hematologists, medical oncologists, infectious disease clinicians, researchers, and investigators who treat or are interested in the management of transplant-related CMV infection. Other allied health care professionals (eg, nurse practitioners, physician assistants, and nurses) involved in the prevention and management of transplant-related CMV infection will also be invited to participate.

Learning Objectives

 

Upon successful completion of this activity, you should be better prepared to:

  • Assess risk factors as well as the impact of CMV on treatment outcomes for patients who undergo HSCT
  • Evaluate evolving strategies for primary and secondary prevention of CMV infection in patients post HSCT
  • Discuss strategies to incorporate evidence-based data and expert recommendations into current clinical practice to prevent and treat CMV infection post HSCT
  • Identify mechanisms leading to the development of resistant CMV infections
  • Review current and emerging strategies to address CMV infections resistant or refractory to current antiviral therapies in patients who undergo HSCT
Additional information

Contact

Name: 
Sherry Fisher
Phone Number: 
+1 (414) 805-0689
Email: 
[email protected]
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 Hours of Participation
    Hours of Participation credit.
Course opens: 
06/23/2022
Course expires: 
06/24/2023
Cost:
$0.00

Accreditation Statement:

The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education to physicians.

Credit Designation Statement:
The Medical College of Wisconsin designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Hours of Participation for Allied Health Care Professionals:
The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.

 

This CME activity is co-provided by The Medical College of Wisconsin and PER, Physician Education Resource, LLC.

Available Credit

  • 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 Hours of Participation
    Hours of Participation credit.

Price

Cost:
$0.00
Please login or register to take this course.